Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Jeffrey L. Wolf, David Siegel, Hartmut Goldschmidt, Katharine Hazell, Priscille M. Bourquelot, Bourras R. Bengoudifa, Jeffrey Matous, Ravi Vij, Margarida De Magalhaes-Silverman, Rafat Abonour, Kenneth C. Anderson, Sagar Lonial

Research output: Contribution to journalLetter

100 Scopus citations
Original languageEnglish (US)
Pages (from-to)1820-1823
Number of pages4
JournalLeukemia and Lymphoma
Volume53
Issue number9
DOIs
Publication statusPublished - Sep 1 2012

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Wolf, J. L., Siegel, D., Goldschmidt, H., Hazell, K., Bourquelot, P. M., Bengoudifa, B. R., ... Lonial, S. (2012). Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 53(9), 1820-1823. https://doi.org/10.3109/10428194.2012.661175